The FDA approved Rinvoq (upadacitinib) as the first and only oral Janus kinase inhibitor for the treatment of giant cell arteritis in adults, providing a steroid-sparing option for achieving sustained remission.
Study demonstrates dose-dependent relationship: each additional menopausal symptom associated with poorer cognitive function and increased behavioral changes in later life.
Conexiant
Daily News
Stay up to date with the latest clinical headlines and other information tailored to your specialty.
Thank you for signing up for the Daily News alerts. You will begin receiving them shortly.
In WHI trial, hormone therapy reduced LDL and insulin resistance but raised triglycerides, with strongest lipoprotein(a) reductions seen in Native and Asian women.